V‘S Ezeofor
Economic model to examine the cost-effectiveness of FlowOx home therapy compared to standard care in patients with peripheral artery disease
Ezeofor, V‘S; Bray, N; Bryning, L; Hashmi, F; Hoel, H; Parker, DJ; Tudor Edwards, R
Authors
N Bray
L Bryning
F Hashmi
H Hoel
Dr Daniel Parker D.J.Parker1@salford.ac.uk
Lecturer in Digital Health
R Tudor Edwards
Contributors
R Serra
Editor
Abstract
Background: Critical limb ischaemia is a severe stage of lower limb peripheral artery disease which can lead to tissue loss, gangrene, amputation and death. FlowOx™ therapy is a novel negative-pressure chamber system intended for home use to increase blood flow, reduce pain and improve wound healing for patients with peripheral artery disease and critical limb ischaemia. Methods: A Markov model was constructed to assess the relative cost-effectiveness of FlowOx™ therapy compared to standard care in lower limb peripheral artery disease patients with intermittent claudication or critical limb ischaemia. The model used data from two European trials of FlowOx™ therapy and published evidence on disease progression. From an NHS analysis perspective, various FlowOx™ therapy scenarios were modelled by adjusting the dose of FlowOx™ therapy and the amount of other care received alongside FlowOx™ therapy, in comparison to standard care. Results: In the base case analysis, consisting of FlowOx™ therapy plus nominal care, the cost estimates were £12,704 for a single dose of FlowOx™ therapy per annum as compared with £15,523 for standard care. FlowOx™ therapy patients gained 0.27 additional quality adjusted life years compared to standard care patients. This equated to a dominant incremental cost-effectiveness ratio per QALY gained. At the NICE threshold WTP of £20,000 and £30,000 per QALY gained, FlowOx™ therapy in addition to standard care had a 0.80 and 1.00 probability of being cost-effectiveness respectively. Conclusions: FlowOx™ therapy delivered as a single annual dose may be a cost-effective treatment for peripheral artery disease. FlowOx™ therapy improved health outcomes and reduced treatment costs in this modelled cohort. The effectiveness and cost-effectiveness of FlowOx™ therapy is susceptible to disease severity, adherence, dose and treatment cost. Research assessing the impact of FlowOx™ therapy on NHS resource use is needed in order to provide a definitive economic evaluation.
Citation
Ezeofor, V., Bray, N., Bryning, L., Hashmi, F., Hoel, H., Parker, D., & Tudor Edwards, R. (2021). Economic model to examine the cost-effectiveness of FlowOx home therapy compared to standard care in patients with peripheral artery disease. PLoS ONE, 16(1), e0244851. https://doi.org/10.1371/journal.pone.0244851
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 17, 2020 |
Online Publication Date | Jan 14, 2021 |
Publication Date | Jan 14, 2021 |
Deposit Date | Jan 15, 2021 |
Publicly Available Date | Jan 15, 2021 |
Journal | PLOS ONE |
Publisher | Public Library of Science |
Volume | 16 |
Issue | 1 |
Pages | e0244851 |
DOI | https://doi.org/10.1371/journal.pone.0244851 |
Publisher URL | https://doi.org/10.1371/journal.pone.0244851 |
Related Public URLs | https://journals.plos.org/plosone/ |
Additional Information | Additional Information : ** From PLOS via Jisc Publications Router ** Licence for this article: http://creativecommons.org/licenses/by/4.0/ **Journal IDs: eissn 1932-6203 **Article IDs: publisher-id: pone-d-20-16557 **History: published_online 14-01-2021; collection 2021; accepted 17-12-2020; submitted 01-06-2020 Grant Number: 737964 Grant Number: 285758 |
Files
pone.0244851.pdf
(1.5 Mb)
PDF
Licence
http://creativecommons.org/licenses/by/4.0/
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Downloadable Citations
About USIR
Administrator e-mail: library-research@salford.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search